Heterocyclic amide for inhibiting RIP1 kinase and uses thereof

1. A compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, optical isomer, racemate, polymorph, solvate or isotopically labeled compound thereof:

wherein

X is O;

Y is C 1 -C 2 alkylene;

Ring A is a benzene ring, a 5-6 membered heteroaromatic ring, a 5-6 membered non-aromatic heterocyclic ring or

and the carbonyl moiety and L 1 connected to Ring A are in meta-positions;

R A is H or C 1 -C 4 alkyl;

L 1 is C 3 -C 6 alkyl, C 3 -C 6 alkoxy, halogenated C 3 -C 6 alkoxy, C 3 -C 6 alkenyl, C 3 -C 6 alkenyloxy, or

wherein

L is O, S, NH, N(CH 3 ), CH 2 , CH 2 CH 2 , CH(CH 3 ), CHF, CF 2 , CH 2 O, CH 2 N(CH 3 ), CH 2 NH or CH(OH);

Ring B is a C 3 -C 6 cycloalkyl, phenyl, 5-6 membered heteroaryl or 5-6 membered non-aromatic heterocyclyl, wherein the C 3 -C 6 cycloalkyl, the phenyl, the 5-6 membered heteroaryl and the 5-6 membered non-aromatic heterocyclyl are each independently unsubstituted or substituted with one or two substituents each independently selected from the group consisting of halogen, C 1 -C 4 alkyl, halogenated C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halogenated C 1 -C 4 alkoxy, nitro and C 1 -C 4 alkyl C(O)—;

R 2 is H or CH 3 ;

Ring M is independently a C 6 -C 10 aromatic ring;

R 1 representative 1-3 substituents each independently being H, halogen, —OH, —CN, —COOH, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 2 -C 10 alkoxyalkyl, C 2 -C 10 haloalkoxyalkyl, C 1 -C 6 hydroxyalkyl, —B(OH) 2 , —S(O) n1 R a , —N(R a ) 2 , —C(═O)N(R a ) 2 , —NHC(═O)R a , —NHC(═O)OR a , —NHC(═O)C(═O)N(R a ) 2 , —NHC(═O)C(═O)OR a , —NHC(═O)N(R a ) 2 , —NHC(═O)NR a C(═O)N(R a ) 2 , —NHC(═O)NR a S(O) 2 OR a , —NHC(═O)NR a S(O) 2 N(R a ) 2 , —NHC(═S)N(R a ) 2 , —NHC(═N—C≡N)NR a , —NHC(═N—C≡N)SR a , —NHS(O) n1 R a , M a , —(C 1 -C 6 alkylene)-B(OH) 2 , —(C 1 -C 6 alkylene)-S(O) n1 R a , —(C 1 -C 6 alkylene)-N(R a ) 2 , —(C 1 -C 6 alkylene)-C(═O)N(R a ) 2 , —(C 1 -C 6 alkylene)-NHC(═O)R a , —(C 1 -C 6 alkylene)-NHC(═O)OR a , —(C 1 -C 6 alkylene)-NHC(═O)C(═O)N(R a ) 2 , —(C 1 -C 6 alkylene)-NHC(═O)C(═O)OR a , —(C 1 -C 6 alkylene)-NHC(═O)N(R a ) 2 , —(C 1 -C 6 alkylene)-NHC(═O)NR a C(═O)N(R a ) 2 , —(C 1 -C 6 alkylene)-NHC(═O)NR a S(O) 2 OR a , —(C 1 -C 6 alkylene)-NHC(═O)NR a S(O) 2 N(R a ) 2 , —(C 1 -C 6 alkylene)-NHC(═S)N(R a ) 2 , —(C 1 -C 6 alkylene)-NHC(═N—C≡N)NR a , —(C 1 -C 6 alkylene)-NHC(═N—C≡N)SR a , —(C 1 -C 6 alkylene)-NHS(O) n1 R a , —(C 1 -C 6 alkylene)-M a , -OM a , -SM a , or N(R a )M a ;

R a at each occurrence is independently hydrogen, C 1 -C 6 alkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, 3-10 membered non-aromatic heterocyclyl, C 3 -C 10 cycloalkyl, or C 5 -C 10 cycloalkenyl, wherein the C 1 -C 6 alkyl, the C 6 -C 10 aryl, the 5-10 membered heteroaryl, the 3-10 membered non-aromatic heterocyclyl, the C 3 -C 10 cycloalkyl and the C 5 -C 10 cycloalkenyl are each independently unsubstituted or substituted with one or two selected from the group consisting of amino, hydroxyl, C 1 -C 4 alkoxy, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, and CN;

M a at each occurrence is independently C 6 -C 10 aryl, 5-10 membered heteroaryl, 3-10 membered non-aromatic heterocyclyl, C 3 -C 10 cycloalkyl, or C 3 -C 10 cycloalkenyl, wherein the C 6 -C 10 aryl, the 5-10 membered heteroaryl, the 3-10 membered non-aromatic heterocyclyl, the C 3 -C 10 cycloalkyl, and the C 3 -C 10 cycloalkenyl are each independently unsubstituted or substituted with one or two selected from the group consisting of halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, and -CN;

n1 at each occurrence is independently 0, 1 or 2;

R is isoxazolyl, oxazolyl, thiazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridinyl, pyrimidinyl, C 3 cycloalkyl, C 6 cycloalkyl,

each independently being unsubstituted or substituted with one substituent selected from the group consisting of F, Cl, methyl, ethyl, isopropyl and cyclopropyl.

2. The compound, or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, optical isomer, racemate, polymorph, solvate or isotopically labeled compound thereof according to claim 1 , wherein, the compound of formula I is selected from the group consisting of the compounds represented by formula Ia:

Z 1 is CH, C(CH 3 ), or C(halogen);

Z 2 is CR 1 ;

Z 3 is CH, C(CH 3 ), or C(halogen);

A, L 1 , X, Y, R, R A , R 1 and R 2 are the same as defined in the formula I of claim 1 .

3. The compound, or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, optical isomer, racemate, polymorph, solvate or isotopically labeled compound thereof according to claim 1 , wherein, the compound of formula I is selected from the group consisting of the compounds represented by formulae Ic and Ie:

Z 1 is CH, C(CH 3 ), or C(halogen);

Z 2 is CR 1 ;

Z 3 is CH, C(CH 3 ), or C(halogen);

A 1 is C;

A 4 is C or N; and

A 2 , A 3 and A 5 are each independently selected from the group consisting of CR A , O, S, N and NR A , so as to form a ring moiety of furyl, thienyl, isoxazolyl, oxazolyl, thiazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, or tetrazolyl, wherein at most one R A is not hydrogen;

A 6 , A 7 , A 8 and A 9 are each independently CR A , wherein at most one R A is not hydrogen; or

one of A 6 , A 7 , A 8 and A 9 is N, and the others of A 6 , A 7 , A 8 and A 9 are CH; or

one of A 6 , A 7 , A 8 and A 9 is N + —O − , and the others of A 6 , A 7 , A 8 and A 9 are CH;

L 1 , X, Y, R, R A , R 1 and R 2 are the same as defined in the formula I of claim 1 .

4. The compound, or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, optical isomer, racemate, polymorph, solvate or isotopically labeled compound thereof according to claim 1 , wherein, the compound of formula I is selected from the group consisting of the compounds represented by formula Ig:

R 1 is H, halogen, —OH, —CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, or C 1 -C 6 haloalkoxy;

X is O;

A 1 is C;

A 4 is C or N; and

A 2 , A 3 and A 5 are each independently selected from the group consisting of CR A , O, S, N and NR A , so as to form a ring moiety of furyl, thienyl, isoxazolyl, oxazolyl, thiazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, or tetrazolyl, wherein at most one R A is not hydrogen;

L 1 , R, and R A are the same as defined in the formula I of claim 1 .

5. The compound, or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, optical isomer, racemate, polymorph, solvate or isotopically labeled compound thereof according to claim 1 , wherein, the compound of formula I is selected from the group consisting of the compounds represented by formula Ii:

R 1 is H, halogen, —OH, —CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, or C 1 -C 6 haloalkoxy;

X is O;

A 6 , A 7 , A 8 and A 9 are each independently CR A , wherein at most one R A is not hydrogen; or

one of A 6 , A 7 , A 8 and A 9 is N, and the others of A 6 , A 7 , A 8 and A 9 are CH; or

one of A 6 , A 7 , A 8 and A 9 is N + —O − , and the others of A 6 , A 7 , A 8 and A 9 are CH;

L 1 , R, R A are the same as defined in the formula I of claim 1 .

6. The compound, or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, optical isomer, racemate, polymorph, solvate or isotopically labeled compound thereof according to claim 1 , wherein, the compound of formula I is selected from the group consisting of the compounds represented by the formula Ik:

R 1 is H, F, Cl, CH 3 , or CH 2 CH 3 ;

R is isoxazolyl, oxazolyl, thiazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridinyl, pyrimidinyl, C 3 cycloalkyl, C 6 cycloalkyl,

each independently being unsubstituted or substituted with one substituent selected from the group consisting of F, Cl, methyl, ethyl, isopropyl and cyclopropyl.

7. A compound, or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, optical isomer, racemate, polymorph, solvate or isotopically labeled compound thereof, wherein,

the compound is selected from the group consisting of the following compounds:

8. A pharmaceutical composition comprising a therapeutically effective amount of one or more selected from the group consisting of the compound of formula (I), and pharmaceutically acceptable salts, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates and isotopically labeled compounds thereof according to claim 1 , and optionally, a pharmaceutically acceptable carrier.

9. A method for treating a disease or disorder or condition in a subject, comprising the step of administering the compound, or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, optical isomer, racemate, polymorph, solvate or isotopically labeled compound thereof according to claim 1 to the subject,

wherein the disease or disorder or condition is selected from the group consisting of inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis, atopic dermatitis, rheumatoid arthritis, spondyloarthritis, gout, SoJIA, systemic lupus erythematosus, Sjogren's syndrome, systemic scleroderma, antiphospholipid syndrome, vasculitis, osteoarthritis, non-alcoholic fatty liver hepatitis, autoimmune hepatitis, autoimmune hepatobiliary disease, primary sclerosed cholangitis, nephritis, celiac disease, autoimmune ITP, transplant rejection, solid organ ischemia-reperfusion injury, sepsis, systemic inflammatory response syndrome, cerebrovascular accident, myocardial infarction, Huntington's disease, Alzheimer's disease, Parkinson's disease, allergic disease, asthma, multiple sclerosis, Type I diabetes, Wegener's granulomatosis, pulmonary sarcoidosis, Behcet's disease, interleukin-I converting enzyme-related fever syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-related periodic syndrome, and periodontitis.